奈达铂联合多西他赛治疗晚期食道癌的临床观察
| 作者: |
1赵惠萍,
2金乔,
3严思奇,
1严文辉
1 湖南省脑科医院，湖南省第二人民医院肿瘤科，长沙 410007 2 中南大学湘雅三医院肿瘤科，长沙 410013 3 中南大学湘雅医院肿瘤科，长沙 410008 |
| 通讯: |
严文辉
Email: csjl@163.com |
| 基金: | 湖南省卫生厅项目(B2013-087) |
摘要
目的：观察奈达铂联合多西他赛治疗晚期食道癌的近期疗效及不良反应。方法：将80例晚期食道癌患者随机分为治疗组和对照组，每组40例，治疗组：采用奈达铂联合多西他赛治疗，其中奈达铂25 mg/(m2.d)第1~3天给予；对照组：采用顺铂联合多西他赛治疗，其中顺铂 25 mg/(m2.d)第1~3天给予，两组均在第1天给予多西他赛75 mg/m2，21天为1个周期。化疗2个周期后按WHO标准评价疗效及毒副作用。结果：治疗组完全缓解2例，部分缓解14例，稳定18例，进展6例，有效率为40.0% (16/40)；对照组完全缓解2例，部分缓解16例，稳定16例，进展6例，有效率45.0% (18/40)，两组有效率比较差异无统计学意义(P>0.05)。治疗组和对照组消化道不良反应分别为10.0%和30.0%；肾毒性分别为0和15.0%，血小板下降分别为30.0%和5.0%，差异有统计学意义(P<0.05)；白细胞减少分别为70.0%和65.0%，差异无统计学意义(P>0.05)。结论：奈达铂联合多西他赛方案与顺铂联合多西他赛方案治疗晚期食道癌的疗效相近，在毒副作用方面多西他赛联合奈达铂方案耐受性良好，具有优势。
关键词：
晚期食道癌；奈达铂；顺铂；多西他赛；有效率；不良反应
Clinical study on the combined chemotherapy with nedaplain and docetaxel for advanced esophageal cancer
CorrespondingAuthor: YAN Wenhui Email: csjl@163.com
Abstract
Objective: To observe the efficacy and adverse reaction of the combined chemotherapy with nedaplatin and docetaxel for patients with advanced esophageal cancer. Methods: A total of 80 patients with advanced esophageal cancer were divided into a treatment group (n=40) and a control group (n=40). Nedaplatin was given intravenously at dose of 25 mg/(m2.d) for three days in the treatment group. Cisplatin was administrated intravenously at dose of 25 mg/(m2.d) for three days in the control group. Docetaxel was infused intravenously at dose of 75 mg/m2 at the first day in both groups. The duration of treatment was 21 days in both groups. The efficacy and toxicity were evaluated according to the standard of WHO at the end of experiments. Results: In the treatment group, there was complete response (CR) in 2 cases, partial response (PR) in 14, stability of disease (SD) in 18 and progress of disease (PD) in 6. The rate of response rate (RR) was 40.0% (16/40). In the control group, there was CR in 2 cases, PR in 16, SD in 16 and PD in 6. The rate of RR was 45.0% (18/40). The rate of RR was similar in the 2 groups (P>0.05). The rate of vomiting in the control group was higher than that in the treatment group (30.0% vs 10.0%, P<0.05). The rate of renal toxicity was 0 in the treatment group and 15.0% in the control group (P<0.05). The rate of hepatic toxicity was all 12.5% in the both groups (P>0.05). The rate of decrease of WBC was 70.0% in the treatment group and 65.0% in the control group (P>0.05). The rate of decrease of platelet was 30.0% in the treatment group and 5.0% in the control group (P<0.05). Conclusion: The nedaplatin combined with docetaxel has the similar therapeutic effect on advanced esophagus cancer to cisplatin combined with docetaxel, and has advantage on the toxicity due to well tolerance by the patients